These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 18218195

  • 1. Lipid abnormalities and cardiovascular risk in the elderly.
    Milionis HJ, Elisaf MS, Mikhailidis DP.
    Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
    [Abstract] [Full Text] [Related]

  • 2. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
    Shah PK.
    Rev Cardiovasc Med; 2011 Mar; 12(2):e55-9. PubMed ID: 21796083
    [Abstract] [Full Text] [Related]

  • 3. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH.
    Am J Cardiol; 2006 Nov 01; 98(9):1231-3. PubMed ID: 17056335
    [Abstract] [Full Text] [Related]

  • 4. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM, Farmer JA.
    Nat Clin Pract Cardiovasc Med; 2006 Dec 01; 3(12):664-72. PubMed ID: 17122799
    [Abstract] [Full Text] [Related]

  • 5. Dyslipidemia as a risk factor at elderly age.
    Wenger NK.
    Am J Geriatr Cardiol; 2004 Dec 01; 13(3 Suppl 1):4-9. PubMed ID: 15133423
    [Abstract] [Full Text] [Related]

  • 6. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA.
    Rev Cardiovasc Med; 2008 Dec 01; 9(4):239-58. PubMed ID: 19122582
    [Abstract] [Full Text] [Related]

  • 7. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.
    Ghandehari H, Kamal-Bahl S, Wong ND.
    Am Heart J; 2008 Jul 01; 156(1):112-9. PubMed ID: 18585505
    [Abstract] [Full Text] [Related]

  • 8. Beyond statin therapy: why we need new thinking.
    Assmann G.
    Curr Med Res Opin; 2005 Jul 01; 21 Suppl 6():S3-8. PubMed ID: 16138935
    [Abstract] [Full Text] [Related]

  • 9. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
    Ferrières J, Bérard E, Crisan O, Bongard V.
    Arch Cardiovasc Dis; 2010 May 01; 103(5):302-9. PubMed ID: 20619240
    [Abstract] [Full Text] [Related]

  • 10. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L, Souchet T, Moulin P, Ritleng C, Desamericq G, Le Jeunne P, Schwalm MS, Van Ganse E.
    Arch Cardiovasc Dis; 2009 Jan 01; 102(1):43-50. PubMed ID: 19233108
    [Abstract] [Full Text] [Related]

  • 11. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG, Zhao XQ.
    Am J Cardiol; 2008 Apr 17; 101(8A):58B-62B. PubMed ID: 18375243
    [Abstract] [Full Text] [Related]

  • 12. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P.
    Am J Manag Care; 2009 Mar 17; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [Abstract] [Full Text] [Related]

  • 13. Prevalence of dyslipidaemia in patients treated with lipid-modifying drugs in the Netherlands. Part of the dyslipidaemia international survey.
    Strang AC, Kaasjager HA, Basart DC, Stroes ES.
    Neth J Med; 2010 Apr 17; 68(4):168-74. PubMed ID: 20421658
    [Abstract] [Full Text] [Related]

  • 14. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M.
    ChemMedChem; 2008 Feb 17; 3(2):206-21. PubMed ID: 17963209
    [Abstract] [Full Text] [Related]

  • 15. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.
    Windler E, Schöffauer M, Zyriax BC.
    Diab Vasc Dis Res; 2007 Jun 17; 4(2):136-42. PubMed ID: 17654448
    [Abstract] [Full Text] [Related]

  • 16. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?
    Rizzo M, Berneis K, Carmina E, Rini GB.
    Am J Obstet Gynecol; 2008 Jan 17; 198(1):28.e1-5. PubMed ID: 18166299
    [Abstract] [Full Text] [Related]

  • 17. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.
    Liberopoulos E, Vlasserou F, Mitrogianni Z, Papageorgantas I, Elisaf M, DYSIS-GREECE Investigators.
    Angiology; 2012 Apr 17; 63(3):184-93. PubMed ID: 21676964
    [Abstract] [Full Text] [Related]

  • 18. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP, Mikhailidis DP, Moross T, Benson K, Gor M.
    Angiology; 2008 Apr 17; 59(1):36-46. PubMed ID: 18319220
    [Abstract] [Full Text] [Related]

  • 19. Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy.
    Rapezzi C, Biagini E, Bellis P, Cafiero M, Velussi M, Ceriello A, Cooke RM, Schweiger C, EASY Investigators.
    J Cardiovasc Med (Hagerstown); 2008 Sep 17; 9(9):878-87. PubMed ID: 18695423
    [Abstract] [Full Text] [Related]

  • 20. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 17; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.